All In MedTech

FDA Clearance Tracker · P970004-S390

InterStim Therapy System, Verify Evaluation System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 18, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 18, 2023

Approved

Time to decision

81 days

Received Sep 28, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P970004-S390
Device name
InterStim Therapy System, Verify Evaluation System
Applicant location
Minneapolis, MN
Received
Sep 28, 2023
Decided
Dec 18, 2023
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P970004

Device type

Device class
Class III
Regulation
21 CFR 876.5270

Every decision under product code EZW

FDA's approval statement

As written in FDA's record.

for labeling updates to the MRI Guidelines manual. The proposed labeling updates are to add the following: 1. MRI eligibility (full-body scans at 1.5T, 3T) criteria for abandoned lead fragments that may remain behind when explant is attempted. 2. MRI eligibility (head-only scans at 1.5T) criteria for a confirmed non-functional primary cell (non-rechargeable) implantable neurostimulator from Medtronic

Source documents

Other decisions for Medtronic Neuromodulation

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

2 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.